LUX-Lung 8: Afatinib Survival Benefit in Squamous NSCLC

The FDA has approved zidesamtinib in patients with locally advanced/metastatic ROS1+ NSCLC who received a prior ROS1 kinase inhibitor.

China's NMPA accepted a supplemental application expanding toripalimab's perioperative NSCLC indication to stage II-III disease.

An updated HARMONi analysis showed a consistent OS benefit with ivonescimab plus chemotherapy in EGFR-mutated NSCLC.

An OncLive workshop covered practice-changing ROS1- and ALK-directed data in NSCLC shared at ASCO 2026 and beyond.

The IL-10–expressing anti-CD19 CAR T-cell therapy produced a 92.9% complete response rate and a 92.9% 1-year overall survival rate in high-risk relapsed/refractory DLBCL.

Two optimized CD33-directed CAR T-cell therapies generated complete remissions with incomplete count recovery in heavily pretreated relapsed/refractory AML.

Lung cancer experts discuss the optimal management of CNS disease in EGFR-mutated non–small cell lung cancer.

Laure-Anne Teuwen, MD, PhD, debates the real-world advantages of subcutaneous pembrolizumab.